PepGen: Maintaining 'Hold,' PGN-EDODM1 Data Is A Major Inflection Point

🇺🇸 Seeking Alpha (US) —

AI Summary

The article maintains a “Hold” rating on PepGen and identifies data from its PGN-EDODM1 program as a major potential inflection point. The supplied description provides no further details about the data or its clinical implications.

Markets Health PepGen PGN-EDODM1 biotechnology clinical data stock rating

Read original source →